Back to Acceleration Radar
LGNDLigand Pharmaceuticals Incorporated
Health Care · Biotechnology: Pharmaceutical Preparations · Mid
$303.53−1.39%
As of 23 Oct 2026Mkt cap $5.7B
Stage 13
AVOID
Fundamentals
33.1/75
Technical
5.6/15
Independent
38.7/90
GCAE viewFundamental /75 is below the Stage 13 acceptable-business floor
Price
- 1M
- +1.5%
- 3M
- +2.0%
- 6M
- +31.2%
- 1Y
- +63.6%
Financials & valuation
Cached filing evidence · as of 2026-10-02
Valuation
- P/E
- 32.3xHist median 40.4x
- Forward P/E
- —No validated forward-estimate source
- Price / FCF
- 46.9x
- FCF yield
- 2.1%
Quality
- ROIC
- 4.0%
- Operating margin
- 9.1%
- FCF margin
- 18.2%
- Current ratio
- 22.2x
Growth
- Revenue growth
- +60.4%Latest FY YoY
- Revenue CAGR
- +2.6%
- EPS CAGR
- +16.7%
- FCF CAGR
- −8.6%
Capital
- Share-count trend
- +6.9%3Y annualised
- Net cash
- $170M-3.4x OCF
Annual trend
- CAGR 2021–2025
- +2.6%
- Latest · 2025
- $0B
- YoY
- +60.4%
GCAE Research
- Quality Research
- NOT FLAGGED
- Acceleration Radar
- FUNDAMENTAL GATE FAIL
- THE ONE
- NOT FLAGGED
- Final / Opportunity
- NOT FLAGGED
Key takeaway
Fundamental /75 is below the Stage 13 acceptable-business floor
Unresolved question
No reliable unresolved question is available from the current committed evidence.
Watch next
- Next earnings · 2026-10-29
More details & evidence
Production decision
- Stage 13
- AVOID
- Technical state
- extended
- Rotation
- tailwind
- Evidence
- fresh
Presentation freshness
- Stage 11 market
- 2026-10-23 · Massive
- Financial cache
- 2026-10-02
- Quality Research
- NOT FLAGGED
- THE ONE
- NOT FLAGGED
Authority
- Company page
- Presentation only
- Scores
- Frozen GCAE production outputs
- Research
- Research-only lanes; no score override
- Private portfolio
- Not loaded